<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" VersionID="3" VersionDate="2024/10/11" Owner="NLM"><PMID Version="3">34458589</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2398-502X</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Wellcome open research</Title><ISOAbbreviation>Wellcome Open Res</ISOAbbreviation></Journal><ArticleTitle>Update to: Study Pre-protocol for "BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study".</ArticleTitle><Pagination><StartPage>120</StartPage><MedlinePgn>120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/wellcomeopenres.16778.3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation's decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.</AbstractText><AbstractText Label="STUDY QUESTION" NlmCategory="UNASSIGNED">We modified our original protocol to conduct a United Kingdom-wide assessment of maternal vaccination against RSV.</AbstractText><AbstractText Label="METHODS AND LIKELY IMPACT" NlmCategory="UNASSIGNED">We will conduct a multi-centre study, utilising the PERUKI network used in the original BronchStart study, to assess the effectiveness of maternal vaccination using a test-negative study design. We will gather detailed clinical information on children admitted with bronchiolitis in the post-RSV vaccination era, and understand possible reasons for incomplete vaccine uptake.</AbstractText><CopyrightInformation>Copyright: © 2024 Williams TC et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-3866-1344</Identifier><AffiliationInfo><Affiliation>Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7342-251X</Identifier><AffiliationInfo><Affiliation>Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drysdale</LastName><ForeName>Simon B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groves</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine at Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iskander</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anthropology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinxue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyttle</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-8634-7210</Identifier><AffiliationInfo><Affiliation>Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emergency Department, Bristol Royal Hospital for Children, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marlow</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Emergency Department, Bristol Royal Hospital for Children, Bristol, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bristol Royal Hospital for Children, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maxwell-Hodkinson</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Liverpool Medical School, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mpamhanga</LastName><ForeName>Chengetai D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Child Life and Health, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Hagan</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine at Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alder Hey Children's Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>Olivia V</ForeName><Initials>OV</Initials><Identifier Source="ORCID">0000-0001-7386-2849</Identifier><AffiliationInfo><Affiliation>Department of Child Life and Health, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatric Infectious Diseases and Immunology, Royal Hospital for Children, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterfield</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine at Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roland</LastName><ForeName>Damian</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9334-5144</Identifier><AffiliationInfo><Affiliation>Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, Leicester Royal Infirmary, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sapphire Group, Health Sciences, Leicester University, University of Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Paediatric Emergency Research in the UK and Ireland (PERUKI)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Wellcome Open Res</MedlineTA><NlmUniqueID>101696457</NlmUniqueID><ISSNLinking>2398-502X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bronchiolitis</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Infants</Keyword><Keyword MajorTopicYN="N">Palivizumab</Keyword><Keyword MajorTopicYN="N">Respiratory Syncytial Virus</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34458589</ArticleId><ArticleId IdType="pmc">PMC8378404</ArticleId><ArticleId IdType="doi">10.12688/wellcomeopenres.16778.3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Williams TC, Lyttle MD, Cunningham S, et al. : Study Pre-protocol for “BronchStart - the impact of the COVID-19 pandemic on the timing, age and severity of Respiratory Syncytial Virus (RSV) emergency presentations; a multi-centre prospective observational cohort study [version 2; peer review: 2 approved]. Wellcome Open Res. 2022;6:120. 10.12688/wellcomeopenres.16778.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16778.2</ArticleId><ArticleId IdType="pmc">PMC8378404</ArticleId><ArticleId IdType="pubmed">34458589</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland D, Williams T, Lyttle MD, et al. : Features of the transposed seasonality of the 2021 RSV epidemic in the UK and Ireland: analysis of the first 10 000 patients. Arch Dis Child. 2022;107(11):1062– 1063. 10.1136/archdischild-2022-324241</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2022-324241</ArticleId><ArticleId IdType="pubmed">36261149</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TC, Marlow R, Hardelid P, et al. : The clinical impact of serious respiratory disease in children under the age of two years during the 2021-2022 bronchiolitis season in England, Scotland and Ireland. J Infect Dis. 2024;230(1):e111–e120. 10.1093/infdis/jiad551</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad551</ArticleId><ArticleId IdType="pmc">PMC11272072</ArticleId><ArticleId IdType="pubmed">39052749</ArticleId></ArticleIdList></Reference><Reference><Citation>
Joint Committee on Vaccination and Immunisation:
Respiratory Syncytial Virus (RSV) immunisation programme for infants and older adults: JCVI full statement, 11 September 2023. GOV.UK,2023; [cited 2023 Nov 19].
Reference Source
</Citation></Reference><Reference><Citation>
RSV vaccination: CMO letter to health boards. gov.scot.2024; [cited 2024 Aug 27].
Reference Source
</Citation></Reference><Reference><Citation>
UKHSA:
Introduction of new NHS vaccination programmes against Respiratory Syncytial Virus (RSV). GOV.UK,2024; [cited 2024 Jul 4].
Reference Source
</Citation></Reference><Reference><Citation>
Introduction of RSV vaccination programme 2024 (WHC/2024/032). GOV.WALES,2024; [cited 2024 Aug 27].
Reference Source
</Citation></Reference><Reference><Citation>
New RSV vaccination programme approved. Department of Health,2024; [cited 2024 Aug 27].
Reference Source
</Citation></Reference><Reference><Citation>Lyttle MD, O’Sullivan R, Hartshorn S, et al. : Pediatric Emergency Research in the UK and Ireland (PERUKI): developing a collaborative for multicentre research. Arch Dis Child. 2014;99(6):602–3. 10.1136/archdischild-2013-304998</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2013-304998</ArticleId><ArticleId IdType="pubmed">24615624</ArticleId></ArticleIdList></Reference><Reference><Citation>
NICE:
Bronchiolitis in children: diagnosis and management. Guidance NICE, [cited 2021 Apr 2].
Reference Source
</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, et al. : The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208. 10.1016/j.jbi.2019.103208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. : Research Electronic Data Capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. 10.1016/j.jbi.2008.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Betsch C, Habersaat KB, Deshevoi S, et al. : Sample study protocol for adapting and translating the 5C scale to assess the psychological antecedents of vaccination. BMJ Open. 2020;10(3): e034869. 10.1136/bmjopen-2019-034869</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-034869</ArticleId><ArticleId IdType="pmc">PMC7066639</ArticleId><ArticleId IdType="pubmed">32161160</ArticleId></ArticleIdList></Reference><Reference><Citation>Betsch C, Schmid P, Heinemeier D, et al. : Beyond confidence: development of a measure assessing the 5C psychological antecedents of vaccination. PLoS One. 2018;13(12): e0208601. 10.1371/journal.pone.0208601</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0208601</ArticleId><ArticleId IdType="pmc">PMC6285469</ArticleId><ArticleId IdType="pubmed">30532274</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization:
Evaluation of COVID-19 vaccine effectiveness.2021; [cited 2024 Jul 25].
Reference Source
</Citation></Reference><Reference><Citation>World Health Organization: WHO COVID-19 vaccine effectiveness measurement tool.2021.</Citation></Reference><Reference><Citation>
UKHSA:
Prenatal pertussis vaccination coverage in England from October to December 2023. GOV.UK,2024; [cited 2024 Jul 25].
Reference Source
</Citation></Reference><Reference><Citation>Dupont WD: Power calculations for matched case-control studies. Biometrics. 1988;44(4):1157–68.</Citation><ArticleIdList><ArticleId IdType="pubmed">3233252</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>